Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
OpenAI Agent Breaches Australia Medicare Data Portal 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Add as a preferred source on Google
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
